These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32733110)

  • 1. Assesment of Risk Factors for Tardive Dyskinesia.
    Vardar MK; Ceylan ME; Ünsalver BÖ
    Psychopharmacol Bull; 2020 Jul; 50(3):36-46. PubMed ID: 32733110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical risk factors for the development of tardive dyskinesia.
    Solmi M; Pigato G; Kane JM; Correll CU
    J Neurol Sci; 2018 Jun; 389():21-27. PubMed ID: 29439776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A descriptive analysis of spontaneous reports of antipsychotic-induced tardive dyskinesia and other extrapyramidal symptoms in the Japanese Adverse Drug Event Report database.
    Saga Y; Chiang CL; Wakamatsu A
    Neuropsychopharmacol Rep; 2024 Mar; 44(1):221-226. PubMed ID: 37884014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V.
    van Harten PN; Hoek HW; Matroos GE; van Os J
    J Clin Psychiatry; 2006 Dec; 67(12):1920-7. PubMed ID: 17194270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
    Misdrahi D; Tessier A; Daubigney A; Meissner WG; Schurhoff F; Boyer L; Godin O; Bulzacka E; Aouizerate B; Andrianarisoa M; Berna F; Capdevielle D; Chereau-Boudet I; D'Amato T; Dubertret C; Dubreucq J; Faget-Agius C; Lançon C; Mallet J; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Llorca PM; Fond G;
    J Clin Psychiatry; 2019 Jan; 80(1):. PubMed ID: 30695288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cumulative Burden of Illness in Veterans With Tardive Dyskinesia and Serious Mental Disorders.
    Caroff SN; Leong SH; Roberts C; Berkowitz RM; Campbell EC
    J Clin Psychopharmacol; 2020; 40(1):38-45. PubMed ID: 31834084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis.
    Patterson-Lomba O; Ayyagari R; Carroll B
    BMC Neurol; 2019 Jul; 19(1):174. PubMed ID: 31325958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of Antipsychotic Use: Antipsychotic-Induced Movement Disorders, with a Focus on Tardive Dyskinesia.
    Dilks S; Xavier RM; Kelly C; Johnson J
    Nurs Clin North Am; 2019 Dec; 54(4):595-608. PubMed ID: 31703784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients.
    Bailey LG; Maxwell S; Brandabur MM
    Psychopharmacol Bull; 1997; 33(1):177-81. PubMed ID: 9133772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of tardive dyskinesia in the elderly: rates and risk factors.
    Woerner MG; Alvir JM; Saltz BL; Lieberman JA; Kane JM
    Am J Psychiatry; 1998 Nov; 155(11):1521-8. PubMed ID: 9812112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Clinical and Economic Burden of Tardive Dyskinesia in Israel: Real-World Data Analysis.
    Barer Y; Ribalov R; Yaari A; Maor R; Arow Q; Logan J; Chodick G; Arkadir D; Eitan R
    J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5):454-460. PubMed ID: 36018237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States.
    Loughlin AM; Lin N; Abler V; Carroll B
    PLoS One; 2019; 14(6):e0216044. PubMed ID: 31163035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness: The Curaçao Extrapyramidal Syndromes Study XII.
    Mentzel CL; Bakker PR; van Os J; Drukker M; Matroos GE; Hoek HW; Tijssen MA; van Harten PN
    J Clin Psychiatry; 2017 Mar; 78(3):e279-e285. PubMed ID: 28199071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Historical perspectives on tardive dyskinesia.
    Caroff SN; Ungvari GS; Cunningham Owens DG
    J Neurol Sci; 2018 Jun; 389():4-9. PubMed ID: 29454494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tardive Dyskinesia.
    Tarsy D
    Curr Treat Options Neurol; 2000 May; 2(3):205-214. PubMed ID: 11096748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis.
    Carbon M; Hsieh CH; Kane JM; Correll CU
    J Clin Psychiatry; 2017 Mar; 78(3):e264-e278. PubMed ID: 28146614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders.
    McEvoy J; Park T; Schilling T; Terasawa E; Ayyagari R; Carroll B
    Curr Med Res Opin; 2019 Jul; 35(7):1205-1214. PubMed ID: 30638073
    [No Abstract]   [Full Text] [Related]  

  • 20. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia.
    Barnes TR
    Psychiatr Dev; 1987; 5(4):301-19. PubMed ID: 2895467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.